| Today’s Big NewsOct 12, 2023 |
| By Fraiser Kansteiner Based on the inclusion criteria for Novo Nordisk’s chronic kidney disease trial, dialysis bigwig DaVita believes there may only be “limited application” of the study’s findings to the overall CKD population. |
|
|
|
By Nick Paul Taylor BioNTech is flattering Daiichi Sankyo through imitation. Six months after picking up an Enhertu rival, the German biotech has paid $70 million upfront for an antibody-drug conjugate (ADC) directed at a second receptor targeted by Daiichi. |
By Conor Hale The European Commission officially ordered Illumina to cut ties with the cancer blood test developer Grail, more than a year after vetoing its acquisition and amid ongoing court battles. |
By Eric Sagonowsky One single comment from a conference call was enough for an appeals court to revive part of an investor lawsuit centered on Biogen's Aduhelm. |
|
Wednesday, October 18, 2023 | 11am ET / 8am PT Join industry experts for an exciting glimpse into the future of pharmaceutical innovation! Gain a comprehensive understanding of the latest strategies in organofluorine-based drug synthesis and learn key insights for staying ahead of the curve in this rapidly evolving landscape. Register now. 
|
|
By James Waldron Almirall will have exclusive global rights to any resulting therapies from the collaboration in return for milestone payments totaling up to $210 million as well as a slice of the royalties. |
By Andrea Park Boston Scientific is hopping on the bandwagon as the latest developer of a spinal cord stimulation system to receive FDA approval for diabetic neuropathy pain relief. |
By Zoey Becker A majority of Crohn's disease patients experienced a clinical response and clinical remission after treatment with mirikizumab, the company said. The results provide a boost after mirikizumab's surprise manufacturing-related FDA rejection in April. |
By Annalee Armstrong A phase 1 study for PepGen’s myotonic dystrophy therapy has been cleared for launch in the U.S. after a five-month FDA clinical hold. |
By Andrea Park The latest nod marks Hyperfine’s eighth FDA clearance in the span of three years for its MRI scanner-on-wheels. |
By Angus Liu Pfizer is expanding the reach of its BRAF-MEK combo as the pharma giant looks to further build up its oncology presence. |
By Nick Paul Taylor Ichnos Sciences has finally found a buyer for its OX40 eczema program. Astria Therapeutics has taken the other side of the deal, paying $15 million upfront to secure a spot at the back of a race led by Amgen and Sanofi. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. |
|
|---|
|
|
|
November 14-15, 2023 | Free Virtual Event The Fierce Diversity, Equity, and Inclusion Forum is back again this year and better than ever. We are collaborating with our Fierce Healthcare Editorial Team to expand the topics and audience for this exciting program across two days. Providing a wide range of strategies and best practices for pharma and biotech companies looking to improve their diversity efforts across all areas of their business.Register now! .png)
|
|
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Edison Ballroom, New York City |
|
|
| |
|
